|

Tucatinib 150 MG Clinical Trials

1 actively recruiting trial

Also known as: Tukysa

Pipeline

Phase 2: 1

Top Sponsors

  • Sunnybrook Health Sciences Centre1

Indications

  • LMD1
  • HER2-positive Breast Cancer1
  • Breast Cancer1
  • Cancer1

Other1 trial

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.